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Resistance to Trypanosoma cruzi infection is dependent on a rapid induction of
Th1-type and CD8+ T cell responses that should be promptly balanced to prevent
immunopathology. T. cruzi-infected B6 mice are able to control parasite replication
but show a limited expansion of Foxp3+regulatory T (Treg) cells that results in the
accumulation of effector immune cells and the development of acute liver pathology.
AhR is a ligand-activated transcription factor that promotes Treg cell development and
suppression of pro-inflammatory cytokine production in dendritic cells, altering the course
of adaptive immune response and the development of immunopathology. Here, we used
different AhR-dependent activation strategies aiming to improve the Treg response, and
B6 congenic mice carrying a mutant AhR variant with low affinity for its ligands (AhRd) to
evaluate the role of AhR activation by natural ligands during experimental T. cruzi infection.
The outcome of TCDD or 3-HK plus ITE treatments indicated that strong or weak
AhR activation before or during T. cruzi infection was effective to regulate inflammation
improving the Treg cell response and regularizing the ratio between CD4+ CD25- to
Treg cells. However, AhR activation shifted the host-parasite balance to the parasite
replication. Weak AhR activation resulted in Treg promotion while strong activation
differentially modulated the susceptibility and resistance of cell death in activated T and
Treg cells and the increase in TGF-β-producing Treg cells. Of note, T. cruzi-infected AhRd
mice showed low levels of Treg cells associated with strong Th1-type response, low
parasite burden and absence of liver pathology. These mice developed a Treg- and
Tr1-independent mechanism of Th1 constriction showing increased levels of systemic
IL-10 and IL-10-secreting CD4+ splenocytes. In addition, AhR activation induced by
exogenous ligands had negative effects on the development of memory CD8+ T cell
subsets while the lack/very weak activation in AhRd mice showed opposite results,
suggesting that AhR ligation restricts the differentiation of memory CD8+T cell subsets.
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We propose a model in which a threshold of AhR activation exists and may explain how
activation or inhibition of AhR-derived signals by infection/inflammation-induced ligands,
therapeutic interventions or exposure to pollutants can modulate infections/diseases
outcomes or vaccination efficacy.
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INTRODUCTION
The aryl hydrocarbon receptor (AhR) is a ligand-activated
transcription factor that plays important roles in several
biological processes, including development, detoxification and
the immune response (1). AhR is expressed in immune system
cells such as macrophages (Mo), dendritic cells (CDs), NK cells,
B lymphocytes and certain subtypes of T cells as Th17 and
Treg cells. When inactive, AhR is located in the cytoplasm as
part of a protein complex which translocate to the nucleus
after ligand activation (1). Genomic AhR signaling pathways
involve the interaction of AhR with other transcription factors to
directly regulate the transcription of target genes through AhR-
responsive elements (AhREs) (1, 2). In immune cells, AhR can
be activated by several physiological ligands that include many
derivatives of tryptophan (Trp) such as L-kynurenine (Kyn)
and 3-hydroxy-kynurenine (3-HK) generated by indoleamine 2,3
dioxygenase (IDO) activity (3, 4) and other endogenous ligands
as the Trp photoproducts 6-formylindolo[3,2-b]carbazole (FICZ)
and 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl
ester (ITE) (5). Also exogenous xenobiotics such as 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) triggers AhR-mediated
signaling (5). AhR activation can regulate innate and adaptive
immune responses via regulation of multiple AhREs present in
the promoter regions of several genes, such as those implicated
in the regulation of NF-kappa-B (6) and the development
of regulatory T cells (Treg) (Foxp3, TGF-β and IL-10) and
Th1 (IL-12), and Th17 (IL-21 and IL-23) cells (1, 2, 7). In
particular, AhR has been shown to regulate the inflammatory
response at different levels, for example imprinting tolerogenic
properties to DCs and promoting the development of regulatory
T cells (Tr1, and CD4+CD25+Foxp3+ Treg cells) (7–9). In
that way, AhR plays an important role in the regulation of
autoimmune inflammatory diseases as rheumatoid arthritis (10),
psoriasis (11) and experimental autoimmune encephalomyelitis
(EAE) (12–14).
Chagas’ disease, caused by the protozoan parasite
Trypanosoma cruzi, represents a major public health problem
in the Americas from Mexico to southern Argentina. Each year
there are approximately 12,000 deaths which are attributable to
Chagas disease, typically due to severe chronic Chagas disease
cardiomyopathy (CCC), which affects approximately 30% of
infected individuals and occurs decades after acute infection (15).
The remaining patients develop digestive disorders (5–10%) or
persist asymptomatic (Asy) and free from cardiac or digestive
disorders (60–70%). Although the mechanisms underlying the
differential progression to CCC are still not fully understood, it
is clear that CCC patients display a more intense inflammation
than Asy patients, who appear to have a more regulated immune
response. The former show increased circulating levels of pro
inflammatory cytokines (16), together with increased numbers
of IFN-γ producing T cells and reduced numbers of IL-10-
producing CD4+ T cells (17–19) and Treg cells (20–22) in
peripheral blood compared with patients having the Asy form of
Chagas disease. In addition, a Th1-rich inflammatory infiltrate
predominantly secreting IFN-γ and TNF is found in the heart
tissue of CCC patients (17, 23–27). Taken together, these results
suggest that, in addition to parasite-mediated damage, the
unbalanced T cell response plays a role in CCC development.
Host resistance during experimental T. cruzi infection is
dependent on a rapid induction of a Th1 inflammatory response
and CD8+ T cell mediated immunity. Th1 mediators are
essential for pathogen control during the acute phase of the
infection while CD8+ T cells are important throughout all the
stages of the infection, although not sufficient for complete
parasite elimination (28). In addition, diverse regulatory
mechanisms should promptly balance the inflammatory response
to prevent the immunopathology. Studies in which C57BL/6
(B6) mice are infected with the Tulahuén strain of T. cruzi
revealed an acute disease accompanied by splenomegaly and
liver damage (29). Likewise to that observed in CCC patients,
B6 mice have great difficulty in controlling the inflammatory
response leading to the premature death of these animals by liver
failure. In this experimental setting, the increased morbidity was
associated to high levels of TNF and low levels of IL-10 (29).
Interestingly, it was demonstrated that B6 mice do not expand
the population of Treg cells in parallel with the large expansion
undergone by the T cell compartment, resulting in an increased
ratio of T effector/Treg cells (30, 31). These results suggest that,
as observed during human Chagas disease, the fatal outcome
in B6 mice may be linked to an unbalanced Th1 response by
poor Treg cell induction. In this way, the severity of T. cruzi-
induced immunopathology may be ameliorated by regulating
the balance of CD4+ effector and Treg cells, and procedures
that change this balance could represent a promising approach
for therapy.
We have previously demonstrated that IDO activity is up-
regulated after T. cruzi infection in mice, being the Trp catabolite
3-HK toxic for T. cruzi amastigotes and trypomastigotes (Tps)
(32, 33). We assayed the treatment of T. cruzi infected BALB/c
mice with 3-HK and observed that, in addition to control
the parasite load, the treatment was able to modulate the
immune response at the acute phase of the infection impairing
the Th1- and Th2-type specific immune response, inducing
TGF-β-secreting cells, promoting the emergence of Treg cells
and markedly reducing the incidence and the severity of the
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inflammatory pathology (32, 34). Because there is a well-
established connection between inflammation, AhR expression
and IDO induction, and considering that Trp-derived IDO-
induced catabolites Kyn and 3-HK AhR ligands may signal AhR
to promote Treg cell induction (3, 4, 35–37), here, we evaluated
the role of physiological AhR signaling and the effect of the
treatment with different AhR agonists on the regulation of the




All animal experiments were approved by and conducted
in accordance with guidelines of the Animal Care and Use
Committee of the Facultad de Ciencias Químicas, Universidad
Nacional de Córdoba (Approval Number HCD 743/18). C57BL/6
(B6) was obtained from School of Veterinary, La Plata National
University (La Plata, Argentina) and B6.D2N-Ahrd/J (AhRd),
kindly provided by Dr. Francisco Quintana (Ann Romney
Center, Boston, USA). All animals were housed in the Animal
Facility of the Facultad de Ciencias Químicas, Universidad
Nacional de Córdoba (OLAW Assurance number A5802-01).
The Tulahuen strain of T. cruzi was used, which was maintained
by weekly intraperitoneal (ip) inoculations in mice.
Treatments and Parasite Load
Groups of B6 mice (6–8 weeks old) maintained under standard
conditions were ip injected with 1 ug of TCDD (AccuStandard,
New Haven, CT, USA) or vehicle (DMSO, Sigma-Aldrich) 24 h
before to be infected with 50,000 bloodstream trypomastigotes
(Tps) of T. cruzi. To evaluate the effect of weak AhR activation
on acute and chronic phase of the infection, B6 mice were
infected with 50,000 T. cruzi Tps, and 5 days post-infection
(pi), were ip injected with 3-HK (1 mg/kg/day, Sigma Aldrich)
for 5 consecutive days (5–10 post-infection) (32, 34) and
with ITE (200 ug Tocris Bioscience, R&D Systems) on days
7, 9, and 11 pi. 3-HK and ITE were resuspended in 0.1M
PBS and DMSO, respectively, with these vehicles also being
employed as control. AhRd mice and its B6 counterpart
were ip infected 50,000 Tps of Tulahuen strain. The levels
of parasitemia were monitored in blood collected at different
times pi as previously described (32). For determination of
tissue parasitism, genomic DNA was purified from liver, heart
and skeletal muscle using TRIzol reagent (Life Technologies)
and following manufacturer’s instructions. Satellite DNA from
T. cruzi (GenBank AY520036) was quantified by real time
PCR using specific Custom Taqman Gene Expression Assay
(Applied Biosystem) using the primer and probe sequences
described by Piron et al (38). A sample containing 200 ng
of genomic DNA was amplified and considered positive for
T. cruzi when the threshold cycle (CT) for the T. cruzi
target when CT <45. Abundance of satellite DNA from T.
cruzi was normalized to GAPDH abundance (Taqman Rodent
GAPDH Control Reagent, Applied Biosystem) and expressed as
arbitrary units.
Transaminase Activity
Plasma aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) activities were measured
using commercial kits (Wiener Lab) following
manufacturer instruction.
Cell Preparations and Culture
Spleen was obtained and homogenized through a tissue
strainer. Erythrocytes in cell suspensions were lysed for
5min in Tris-ammonium chloride buffer (Sigma Aldrich),
washed and resuspended in complete medium, containing
RPMI 1640 (Gibco,) supplemented with 2mM GlutaMAX
(Gibco, ThermoFisher), 10 ug/ul gentamicin (Richet S.A,
CABA, Argentina) and 10% FBS (NATOCOR, Cordoba,
Argentina). Viable cell numbers were determined by trypan
blue exclusion using a Neubauer counting chamber. For
cytokine determinations, spleen mononuclear cells (SMC) were
cultured with or without T. cruzi lysate (1 mg/ml) at 2 ×
106 cells/ml in complete RPMI medium in 24-well plates
(Costar) for 72 h. Supernatants were collected and the secreted
cytokines measured.
Cytokine Quantification
Cytokines were measured in sera and cell culture supernatants
by capture ELISA using antibodies and protocols suggested
by the manufacturer (eBiociences, ThermoFisher). Cytokine
concentration in serum samples was expressed as pg/ml,
while the cytokine levels in culture supernatants were
represented as Index obtained by dividing the cytokine
concentration in supernatant of T. cruzi-stimulated
cultures/cytokines concentration in supernatants of
non-stimulated cultures (medium).
Flow Cytometry
Cell suspensions were washed in ice-cold FACS buffer (PBS-2%
FBS) and incubated with fluorochrome labeled-Abs for 20min
at 4◦C. Different combinations of the following Abs were used:
anti-CD25-PeCy7 (eBiociences, ThermoFisher), anti-CD25-APC
(eBiociences, ThermoFisher), anti-CD4-PerCp5.5 (eBiociences,
ThermoFisher), anti-CD44-PECy7 (eBiociences, ThermoFisher),
anti-CD62L-APCCy7 (BD Bioscience), anti CD8-FITC (BD
Bioscience), anti-FR4-FITC (eBiociences, ThermoFisher), anti-
LAP-PeCy7 (eBiociences, ThermoFisher) and an H-2K(b)
T. cruzi trans-sialidase amino acids 569-576 (ANYKFTLV)
(TSKB20) APC-Labeled Tetramer (NIH Tetramer Core Facility),
which was used for staining 15min before the addition of the
rest of the surface markers. Intracellular cytokines were detected
after stimulating cells during 4 h with 50 nM PMA (Sigma
Aldrich) and 0.5µg/ml ionomycin (Invitrogen, ThermoFisher),
or 10µg/ml T. cruzi lysate in the presence of GolgiStop (BD
Biosciences). Cells were surface-stained, fixed, and permeabilized
with BD Cytofix/Cytoperm and Perm/Wash (BD Biosciences)
according manufacturer’s instruction and intracellular stained
with anti-IL-10-APC (eBiociences, ThermoFisher), anti-IL-10-
PE (eBiociences, ThermoFisher), anti-IL-17-PE (eBiociences,
ThermoFisher), anti-IFN-γ-APC (eBiociences, ThermoFisher),
and anti-Foxp3-PE (eBiociences, ThermoFisher). For Annexin
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V and 7-AAD staining, the Apoptosis detection kit I (BD
Pharmingen) was used. Then, were washed and acquired in
FACSCanto II (BD Biosciences). For LAP staining the cells were
activated with PMA and ionomycin during 4 h in the absence
of GolgiStop.
Statistical Analysis
Data distribution was analyzed with Shapiro-Wilk test. Normally
distributed data were presented as means ± SD. Differences
between the mean values were assessed using Student’s t-
test. Differences on survival were analyzed applying Gehan-
Breslow-Wilcoxon test. Results were considered significantly
different when p < 0.05. Statistic was performed using GraphPad
Prism7 software.
RESULTS
Activation of AhR With TCDD Impairs Host
Resistance to T. cruzi Experimental
Infection
Evidence from studies to control autoimmunity and graft-
vs.-host disease, even virus induced inflammatory lesions
indicate that the regulation of the immune response to avoid
immunopathology could be achieved by the administration of
the stable agonist of AhR, TCDD (7, 39–41). TCDD is a non-
degradable high affinity ligand for AhR and most studies using
this ligand have reported inhibitory effects on inflammatory
reactions (40, 41).
To evaluate the role of AhR engagement by TCDD on
the outcome of T. cruzi infection, a single intraperitoneal (ip)
administration of TCDD was given to mice 1 day prior to
infection and the effects on parasite load, host survival and
protective immune response were compared with vehicle-treated
controls. TCDD treatment impaired resistance to infection as
treated mice showed increased parasitemia and serum levels of
ALT and AST that resulted in decreased survival compared to
control mice (Figures 1 A–C). In addition, the treatment with
TCDD did not affect survival or adversely affect hepatic enzymes
levels in uninfected mice (Figure 1C and data not shown),
suggesting that the dose of TCDD used did not present toxic
effects per se.
To measure the consequences of TCDD treatment on
the specific immune response, mice were sacrificed during
the acute phase of infection (day 10 post-infection). At the
time of sacrifice TCDD-treated mice showed spleens markedly
decreased in size and cell numbers compared with non-treated
infected mice, which showed the characteristic infection-induced
splenomegaly (Figure 1D).
To determine the effect of TCDD treatment on Th cell
polarization, SMC from treated and control mice were stimulated
in vitro for 4 h with PMA and ionomycin to enumerate
cells that produced either IFN-γ or IL-17. In addition, the
frequencies of CD8+ T cells specific for the immunodominant
epitope TSKB20 (ANYKFTLV) (42) and Foxp3+ CD25+ CD4+
Treg cells were also evaluated. Compared with non-infected
controls, T. cruzi infected mice showed significantly increased
percentages and absolute numbers of CD4+ cells producing
IFN-γ and IL-17 while the TCDD treatment resulted in marked
decrease in the percentage and absolute number of these
effector cell subsets (Figure 1E). In addition, TCDD-treated mice
showed a significant reduction of specific CD8+ TSKB20/Kb+
cells (Figure 1F).
To investigate whether TCDD treatment differentially affected
cell survival of infection-activated T. cruzi-specific T cells, we
compared the level of cell death in the CD8+ TSKB20/Kb+
population from TCDD-treated and control mice by assaying
Annexin V binding and 7-AAD permeability. T. cruzi-specific
CD8+ T cells from TCDD-treated mice showed lower frequency
of live cells (Annexin V-, 7-AAD-) and higher frequency of
dead cells (Annexin V+, 7-AAD+/-) than those from control
mice (Figure 1G), suggesting a direct toxic effect of TCDD on
parasite-activated cells.
When the effect of TCDD treatment on CD4+ CD25+
Foxp3+ Treg population was evaluated, it was observed that
although the numbers of splenic Treg cells were not significantly
different between both experimental groups, the percentage
of Treg cells and the number of Treg cells producing the
immunoregulatory cytokine TGF-β were significantly higher in
TCDD-treated compared to control mice, while no differences
were observed for IL-10-secreting Treg cells (Figures 2A,B). In
addition, TCDD treatment decreased the ratio between total
numbers of CD4+CD25- (conventional CD4+ T cells), Th1 cells
(IFN-γ-producers) and Th17 cells (IL-17-producers) and total
numbers of Treg cells (Figure 2C). Of note, TCDD treatment
normalized the ratio of total and effector cytokine-producing
conventional CD4+ T cells and Treg cells to values similar to
those observed in uninfected mice (Figure 2C). These findings
suggested that Treg cells are much less sensitive to TCDD-
induced death than conventional T cells. To evaluate this
hypothesis, we analyzed comparatively the level of cell death in
the CD4+ FR4hi cell population [phenotype compatible with
Treg cells (43)] from treated and control mice. Figure 2D shows
that the level of cell death in the Treg cell population from
TCDD-treated and control mice was similar.
Given the results described above, TCDD might be effective
to induce regulation of the inflammatory response in T. cruzi
infected B6 mice but would not be recommended for usage
during the induction of the immune response triggered by the
initial parasite replication. With this in mind, we performed
additional experiments in which TCDD treatment was given on
day 7 pi, a time point in which the innate and effector T cell
response is ongoing and the inflammation-induced damage may
begin to become apparent. Although TCDD administration on
day 7 pi prolonged the survival of TCDD-treated mice, it still
increased mice mortality in comparison to controls (not shown).
Combined AhR Agonists Promote Treg Cell
Differentiation and Have Detrimental
Effects on Parasite-Specific Immunity
As TCDD, the endogenous AhR ligand ITE is able to induce
Treg cells (12, 44, 45), but is nontoxic and could, therefore,
be useful to modulate the inflammatory response without a
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FIGURE 1 | TCDD treatment suppress T cell expansion, cytokine production, and impairs resistance to T. cruzi infection. C57BL/6J mice were ip injected with TCDD
or DMSO (Control) 24 h before being infected with 50,000 Tps of T. cruzi. (A) Parasitemia (Tps/ml blood). Data are shown as mean ± SD of 7-9 mice per group.
(Continued)
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FIGURE 1 | (B) ALT and AST activity determined in plasma at day 10 and 17 pi. Data are shown as mean ± SD, n = 3 mice per group. (C) Survival rate of
non-infected TCDD treated (NI TCDD), infected TCDD-treated and infected vehicle-treated (control) mice. P-values were calculated with the Gehan-Breslow-Wilcoxon
test. (D) Images of spleens from NI and infected TCDD-treated and control mice in one representative experiment. The bars represent the number of total spleen cells
from NI and infected TCDD-treated and control mice ± SD. (E) Splenocytes taken from NI (n = 4) and T. cruzi-infected mice treated (TCDD, n = 5) or not (Control, n =
4) with TCDD at day 10 pi were in vitro stimulated with PMA/Ionomycin in the presence of Golgi stop. The bars represent the percentage and absolute number of
CD4+ splenocytes producing IFN-γ or IL-17 cytokines. (F) Representative dot plots (top) and bars showing the percentage and absolute number (bottom) of
splenocytes CD8+ TSKB20/Kb+ from control and TCDD-treated mice at day 10 pi. (G) Representative dot plots (left) and bars (right) showing the percentage of
Annexin V- 7-AAD- and Annexin V+ 7AAD+/- splenic cells within the CD8+ TSKB20/Kb+ population at day 10 pi. Bars represent the mean values ± SD. Data in A-C
and in D–G are representative of three and two independent experiments, respectively. P-values were calculated with two-tailed Student’s t-test. *p < 0.05,
**p < 0.01, ***p < 0.001.
FIGURE 2 | TCDD treatment shifted the balance between inflammatory and CD4+ CD25+ Foxp3+ Treg cells. (A) Representative dot plots (right) and bars (left)
showing the percentage and absolute number of splenocytes from NI, control and TCDD-treated mice expressing CD25+ Foxp3+ within CD4+ population at day 10
pi. Bars are shown as mean ± SD, n = 3 mice per group. (B) Absolute number of CD4+ CD25+ Foxp3+ IL-10+ and CD4+ CD25+ Foxp3+ LAP+ splenocytes after
PMA/Ionomycin stimulation at day 10 pi. Bars are shown as mean ± SD, n = 3 mice per group (C) Ratio of splenic effector T cells (CD4+CD25-), Th1 cells
(CD4+Foxp3-IFNγ-) and Th17 cells (CD4+ IL-17+) to Treg cells (CD4+CD25+Foxp3+). Bars represent mean values ± SD with n = 3 mice per group. (D)
Percentage of Annexin V- 7-AAD- and Annexin V+ 7AAD+/- spleen cells within the CD4+ FR4+ population. Data in A-C and in D are representative of three and two
independent experiments, respectively. P-values were calculated with two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ****p < 0.0001.
cytotoxic effect on parasite-specific T cells. Furthermore, it has
been demonstrated that 3-HK is a weak AhR agonist (3) and also
it is active against the amastigote and trypomastigote forms of
T. cruzi (32, 34). Considering the background mentioned above,
we developed a treatment scheme to simultaneously activate
AhR and inhibit T. cruzi replication that consisted in the daily
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FIGURE 3 | 3-HK plus ITE treatment promotes the differentiation of Treg cells with detrimental effects on protective immune response. (A) T. cruzi-infected B6 mice
were treated with 3-HK plus ITE with vehicle-treated mice used as control (PBS+DMSO). (B) Percentage, absolute number of splenic CD25+ Foxp3+ cells within
(Continued)
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FIGURE 3 | CD4+ population and ratio of effector T cells (CD4+CD25-) to Treg cells (CD4+CD25+Foxp3+) at days 13 and 90 pi. Bars are shown as mean ± SD
with n = 3 mice per group. (C) Absolute number of splenic CD4+ CD25+ Foxp3+ LAP+ cells at 90 days pi after PMA/Ionomycin stimulation. Bars are shown as
mean ± SD with n = 3 mice per group. (D) Cytokine levels assayed in supernatants of splenocytes taken at 22- and 90-days pi and cultured with medium alone or
total T. cruzi lysate for 72 h. The results are represented as an Index which is the ratio between cytokine concentration in supernatant of T. cruzi-stimulated cultures
and cytokine concentration in the corresponding not stimulated culture. (E) Percentage of splenic cells CD4+ TNF+ cells at 22 days pi after 4 h of PMA/Ionomycin
stimulation. (F) Relative amount of T. cruzi satellite DNA in heart and liver at day 90 pi. GAPDH was used as endogenous control for normalization. One experiment
representative of two independent is shown. P-values were calculated with two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ****p < 0.0001.
administration of 3-HK from days 5 to 10 pi together with
ITE injection at days 7, 9, and 11 pi, as depicted in Figure 3A.
The cellular immune response and the levels of parasite load
in the target tissues were then investigated. Acutely infected
mice treated with 3-HK plus ITE did not show differences in
parasitemia and survival compared with control mice (Figure S1
in Supplementary Material). However, T. cruzi-infected B6 mice
treated with ITE plus 3-HK had a significant increase in the %
(day 13 and 90 pi) and number (day 90 pi) of splenic Treg cells
(Figure 3B), and in the number of Treg cells producing TGF-β
(day 90 pi) (Figure 3C) when compared with controls. Moreover,
3-HK plus ITE treatment reversed the characteristic unbalanced
ratio between conventional CD4+ T cells to Treg cells to values
like those observed in uninfected mice (Figure 3B).
To evaluate the cellular immune response developed in 3-
HK plus ITE-treated mice, the Ag-specific cytokine production
was analyzed in SMC taken at different times pi after ex vivo
restimulation with parasite lysate. T. cruzi-stimulated SMC taken
from mice treated with 3-HK plus ITE at the acute phase of
the infection (day 22 pi) secreted significantly lower amounts of
TNF and IFN-γ and higher amounts of IL-10 than those from
untreated mice (Figure 3D). In agreement, treated mice showed
a significant lower percentage of TNF-producing spleen CD4+
T cells than control mice (Figure 3E). In addition, only a small
increase in the production of IFN-γ by T. cruzi-stimulated SMC
was observed in treated vs. control mice during the chronic phase
of the infection (90 days pi).
Finally, to determine whether the 3-HK+ITE-induced
regulation of the specific response compromised the protective
immunity to T. cruzi, the parasite load was determined in liver
and heart at 90 days pi. Compared with untreated, the mice that
had been treated with 3-HK plus ITE showed higher parasite
load in both liver and heart (Figure 3F). This increased parasite
burden could underlie the higher production of IFN-γ by SMC
from chronically infected 3-HK plus ITE-treated mice.
Together, our results suggest that 3HK plus ITE might be
a novel therapeutic treatment able to control the inflammatory
response. However, considering our results and a recent report
(31) the expansion of Treg cells during the acute phase of T.
cruzi infection with T. cruzi may also prevent the emergence
of protective anti-parasite immunity and critically influence
host resistant.
AhRd Mice Develop a Proper Inflammatory
and Anti-inflammatory Response Able to
Restrict Parasite Replication
To investigate further on the role of AhR activation during the
T. cruzi infection and considering that endogenous AhR ligands
are generated during this infectious process, we took advantage
of AhRd mice, a congenic B6 mice expressing a mutant AhR
protein with reduced affinity for its ligands (46). AhRd and WT
mice were infected and parasitemia, tissue parasite load, survival
and the splenic T cell populations were studied during the acute
and the chronic phase of the infection. Infected AhRd mice
presented significantly lower peak of parasitemia (Figure 4A),
had prolonged survival compared to WT mice (Figure 4B) and
displayed significantly lower levels of the hepatic transaminase
ALT in sera (Figure 4C). AhRd mice also showed at day 10
pi an expansion of CD4+ IFN-γ producing cells compared
withWTmice and (Figure 4D), somehow contrasting previously
reported association of high Th1-type response and liver tissue
damage in B6-infected mice (29). In addition, we found a strong
increase in the number of splenic as well as IFN-γ-producing
cells between days 10 and 17 pi in WT, but not in AhRd,
mice (Figure 4D). As expected, and consistent with the low
strength of AhRd signaling (3, 7), the number of splenic Treg
cells was significantly lower in AhRd compared to WT mice
(Figure 4D). Also, B6- and AhRd-infected mice showed similar
levels of CD4+ IL-17-producing cells (not shown). Interestingly,
whereas the levels of pro-inflammatory cytokines in sera were
similar in both mice groups (data not shown), the levels of IL-
10 in sera and the % of IL-10-producing cells were significantly
higher in AhRd vs. WT mice during the acute phase of the
infection (Figures 4E,F), being a CD4+ cell population the
main producer of this cytokine at day 10 pi (Figure 4F). In
addition, AhRd mice exhibited lower number of parasite-specific
IFN-γ-producing splenocytes during the chronic phase of the
infection, in concordance with lower parasite load in liver, heart
and skeletal muscle compared with WT mice (Figures 4G,H).
Taken together, these results indicate that AhR signaling is
critically involved in the development of robust parasite-specific
Th1 responses and immunoregulatory mechanisms during T.
cruzi infection.
AhR Signaling Restricts the Differentiation
of Memory CD8+ T Cell Subsets During
T. cruzi Infection
The acquisition of memory T cells is defined by the generation
and persistence of T cells that can provide long-lasting protection
against pathogens. Signals given by DC as TCR engagement,
costimulation and cytokines co-participate in the induction of
memory T cells. Thus, changes in any of the factors controlling
the activation of T cells during the antigen presentation can
regulate T effector and memory cell differentiation. Different
observations suggest that AhR, directly or through its effects
on antigen presenting cells modulates critical events in the
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FIGURE 4 | AhRd mice develop a proper inflammatory and anti-inflammatory response able to restrict parasite replication. AhRd and WT mice infected with 50,000
Tps of T. cruzi were evaluated for parasitemia, survival and other groups sacrificed at days 10, 17, and 170 pi. (A) Parasitemia (Tps/ml blood). Data are shown as
mean ± SD, n = 5 mice per group (B) Survival rate of T. cruzi infected WT and AhRd mice, n = 5 mice per group. (C) ALT activity determined in sera at day 17 pi. (D)
Absolute number of CD4+ IFNγ+ and CD4+ CD25+ Foxp3+ cells in spleen from WT- and AhRd-infected mice at day 10 and 17 pi. (E) Levels of IL-10 in sera from
NI, and infected WT and AhRd mice at day 10 pi. (F) Percentage of total, CD4+ and CD4- splenocytes that produce IL-10 after PMA/Ionomycin stimulation at day-17
pi. (G) Absolute number of CD4+ IFNγ-producing splenocytes at day 170 pi after in vitro stimulation with T. cruzi total lysate (10 ug/ml). (H) Relative amount of T. cruzi
satellite DNA in heart, liver and skeletal muscle from WT and AhRd mice at day 170 pi. GAPDH was used as endogenous control for normalization, n = 4 mice per
group. One experiment representative of three independent experiments is shown. P values were calculated with two-tailed Student’s t-test. *p < 0.05, **p < 0.01,
***p < 0.001.
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activation of naive T cells that could modify the development
of effector and memory T cells (47, 48). To evaluate the
role of AhR activation on T cell differentiation of different
memory subsets, we evaluated the effect of different strength
of AhR ligation on the frequencies of CD8+ total and specific
(TSKB20/Kb+) cell subsets defined by CD62L and CD44
expression. Figure 5A shows that strong AhR ligation with
TCDD significantly decreased the frequency of CD8+ CD44hi
CD62Llo cells (effector/effector memory cells, EM) and the
number of both EM and CD8+ CD44hi CD62Lhi cells (central
memory cells, CM) in spleen at day 10 pi. Moreover, the
number of splenic T. cruzi-specific (TSKB20/Kb+) EM and
CM subpopulations showed a significant decrease in treated
compared with control mice. These results suggest a negative
effect of a strong AhR activation on the development of
effector and memory CD8+ T cells precursors. However, the
fact that antigen-experienced cells suffer the direct effect of
TCDD toxicity (Figure 1G), does not allow to conclude clearly
on the consequence of AhR ligation on the development of
memory precursor cells. Indeed, CD8+ TSKB20/Kb+ cells
with EM phenotype from TCDD-treated mice showed higher
percentage of Annexin V+ 7-AAD+ cells than those from
control mice (Figure 5B).
To test the hypothesis that the activation of AhR might
alters the in vivo distribution and frequency of CD8+ total and
parasite-specific T cells subsets, we analyzed the effector phase
of memory induction in T. cruzi infected B6 mice that were
treated with 3-HK plus ITE as depicted in Figure 3A. Figure 5C
shows that weak AhR ligation with 3HK plus ITE during T. cruzi
infection decreased the percentage of total and specific CD8+
splenic T cells that acquired EM and CM phenotype.
To support these findings, we compared the frequency and
number of total and T. cruzi-specific CD8+ T cells with EM
and CM phenotype in AhRd and WT mice after 17 and 170
days pi. Similar frequency and number of CD8+ T cells specific
for the immunodominant epitope TSKB20 were observed for
AhRd and WT mice at day 20 pi (not shown). Moreover, and in
contrast to that observed when AhR was activated by exogenous
ligands (Figures 5A,C), the frequency of CD8+ total and T.
cruzi-specific T cells with EM phenotype was higher in AhRd
than WT mice at 17 days pi (Figure 6A) and during the chronic
phase of the infection (day 170 pi) (not shown). Interestingly,
AhRd mice showed higher percentages and absolute number
of CD8+ total and T. cruzi-specific T cells than WT mice at
the chronic phase of the infection (day 170 pi) (Figure 6B).
Analysis of CD44 and CD127 expression, that distinguish central
memory cells (CD44hi CD127hi) from effector memory cells
(CD44hi CD127lo), in subpopulations of CD8+TSKB20/Kb+ T
cells revealed that the frequency and number of splenic cells
with CM phenotype was significantly higher in AhRd than in
WT mice during the chronic phase of the infection (Figure 6C
and not shown). Taken together, these results suggested that
during T. cruzi infection physiological AhR ligation restricts
the differentiation of CD8+ memory T cells impacting in the
magnitude of the long-term parasite-specific immune response
and the chronic control of tissue parasitism.
DISCUSSION
It has been demonstrated that AhR activation can be induced
by diverse ligands in the environment, however, Trp metabolites
have emerged as key family of physiological agonistic ligands
(49). During T. cruzi infection, the up-regulation of the enzyme
IDO tht catalyzes the Trp degradation along the Kyn pathway
has at least two main roles, the control of pathogen growth
by producing the catabolite 3-HK and the immune regulation
facilitated by the 3-HK-mediated expansion of Treg cells (32, 34).
IDO induction depends on AhR expression, and Kyn as well as 3-
HK are both AhR ligands that signal for Treg induction (3, 4, 35).
Thus, the AhR agonist 3-HK used as a therapy in T. cruzi-infected
BALB/c mice was able to increase the Treg population and to
modify the outcome of the infection (34).
After T. cruzi infection, B6 mice develop an important Th1-
type response able to control the parasite replication (29).
However, and likewise to that observed in CCC patients, T.
cruzi-infected B6 mice have great difficulty in controlling the
inflammatory response, resulting in the premature death by liver
failure, being the increased morbidity associated to high levels of
TNF and low levels of IL-10 in sera and the incapacity to expand
Treg population (29–31). It is known that immune responses can
be enhanced or dampened by differential manipulation of Treg
cells vs. other naive or activated T cells. In this study, we have
assayed different AhR activation-dependent strategies aiming to
specifically boost Treg cells in B6 mice infected with T. cruzi.
The results obtained by TCDD treatment indicated that strong
AhR activation during T. cruzi infection can normalize the ratio
between Th1 and Th17 to Treg cells. Our results showed that
the balance of the inflammatory response observed after TCDD
treatment was the result of the increased death of activated T
cells, the increase in the number of Treg cells producing the
immunoregulatory cytokine TGF-β and the resistance of these
cells to TCDD-induced death, with no significant changes in the
frequency or number of IL-10 producing cells between control
and treatedmice. It is worth tomention that the direct toxic effect
of TCDD on activated T cells has been previously demonstrated
(50). In addition, Winans et al. (51) have shown that CD8+
T cells exposed to TCDD exhibit methylation patterns similar
to those of exhausted CD8+ T cells suggesting that a strong
AhR ligation has an important impact on basal functionality
and initial responses to antigenic stimulation, and also explains
the decreased memory cell subsets showed in this paper for
T. cruzi-infected TCDD-treated mice. As far as we know, the
resistance to TCDD toxicity by Treg cells has not been described.
Taking into account that murine and human Treg cells are more
resistant than activated non-Treg CD4+ T cells to apoptosis
induced by different pathways such as irradiation, Fas ligation
and viral infection (52–55), it should not be surprising that
these cells would be also resistant to strong AhR activation.
Thus, strong AhR activation with TCDD was effective to regulate
inflammation in T. cruzi infected B6 mice, but the TCDD-
induced immunosuppression contributed to parasite replication,
and the treatment resulted in increased parasitemia and death of
the treated mice.
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FIGURE 5 | AhR ligation regulates the development of memory CD8+ T subsets during T. cruzi infection. Splenocytes from TCDD- and 3HK + ITE-treated mice and
its respective controls were isolated at day 10- and 22-days pi to evaluate total CD8 and TSKB20/Kb-specific memory subpopulations by flow cytometry.
(Continued)
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FIGURE 5 | (A) Representative plots, percentage, and absolute number of splenocytes from control and TCDD-treated mice at day 10 pi showing effector/memory
(EM, CD44+CD62L−) and central memory (CM, CD44+CD62L+) phenotype on CD8+ and CD8+ TSKB20/Kb+ cell populations gated as described in Figure S2A
in Supplementary Material. Bars represent the mean values ± SD. Control, n = 5 and TCDD, n = 4. (B) Representative plots and bars showing the percentage of
splenocytes expressing Annexin V- 7-AAD-, Annexin V+ 7AAD- and Annexin V+ 7AAD+ cells within the CD8+ TSKB20/Kb+ EM cell population of Control and
TCDD treated mice at day 10 pi. Bars represent the mean values ± SD. Control, n = 5 and TCDD, n = 4. (C) Representative plots and bars showing the percentage
of splenocytes from control and 3-HK plus ITE-treated mice with EM and CM phenotype within CD8+ and CD8+ TSKB20/Kb+ cell populations (gated as indicated in
Figure S2B of Supplementary Material) at day 22 pi. Bars represent the mean values ± SD. Control, n = 3 and 3-HK+ITE, n = 3. One experiment representative of
three independent experiments is shown. P-values were calculated with two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001.
The other strategy used to induce Treg cells in B6 mice
was to treat the mice with two weak AhR ligands, ITE and 3-
HK, to simultaneously activate AhR and concomitantly inhibit
parasite replication (32–34). Once more, although this treatment
was able to induce Treg cells and improve the unbalanced ratio
between CD4+ CD25- to Treg cells during the chronic phase
of the infection, the fact that 3-HK is only partially efficient in
controlling the parasitemia and unable to eradicate the parasite
(32), shifted the host-parasite balance to the parasite replication.
Indeed, although 3-HK plus ITE-treated and control mice did not
have significant differences in parasitemia and survival during
the acute phase of the infection, treated mice showed higher
parasite load in both liver and heart during the chronic phase.
Considering that TNF and IFN-γ are both critical cytokines
to mediate protection while IL-10 mediates susceptibility in T.
cruzi infection (56), the increase in parasite load was in line
with the lower IFN-γ and TNF and higher IL-10 production by
splenocytes from 3-HK plus ITE treated mice during the acute
phase of the infection.
Thus, the results obtained by using two different experimental
strategies to promote Treg development by AhR activation
demonstrated that the increase of the number of Treg did
not ameliorate the immunopathology issue, since limited Treg
response during T. cruzi infection in B6 mice is critically
required to allow the development of protective parasite specific
T cell immunity, as was recently reported by Araujo et al. (31).
Decrease host resistance to a variety of infectious agents has
been reported when TCDD exposure occurs prior to infection,
however, whether the AhR ligation contributes to improve or
worsen host resistant depends on the pathogen (48). Thus, in
contrast to what is observed for T. cruzi infection, AhR activation
by TCDD in Leishmania major infection reduces the parasite
burden (57, 58).
It has also been reported that AhR signaling under Tr1-
skewing conditions (IL-27 or TGF-β plus IL-27) promotes the
differentiation of Tr1 cells (CD4+ IL-10+) (59). However,
neither TCDD nor 3-HK plus ITE treatments were able to
significantly increase Tr1 population [CD4+, Foxp3-, IL-10+
Lag-3+ cells (60)] in T. cruzi-infected B6 mice (data not shown),
in spite of both treatments up-regulated TGF-β production and
T. cruzi infection induces IL-27 production in B6 mice (30).
By using AhR-/- (KO) mice, Barroso et al. have examined
the role of AhR in the immune modulation and development
of myocarditis during T. cruzi infection (61), and some of the
findings reported in their work correlate with our findings in
AhRd mice. It has been reported that besides being refractory to
most of the TCDD toxic effects, AhR KO mice exhibit multiple
physiological abnormalities that are independent of xenobiotic
exposure (62). The fact that AhR KO mice present an abnormal
development of the immune system and the liver (63), should be
an important constraint for evaluate the role of this receptor in
modulating immune response and liver pathology in a model of
infection in which the main target of pathological inflammation
is the liver, and not the heart as in infected human patients or
BALB/c mice. For that reason, we decided to evaluate the role of
AhR activation by natural ligands (as Trp metabolites) generated
during T cruzi infection by using B6-AhRd congenic mice. AhRd
mice express an AhR with a 10-fold lower binding affinity for
TCDD, and required a 10-fold higher dose of TCDD than AhRb-
1 allele, present in B6 mice, to elicit similar effects (46). We
have found that these mice suffer a more pronounced collapse
of the Treg population than WT mice, which is consistent
with weak/lack of AhR activation (3, 7). As expected, low Treg
levels were associated to a stronger Th1 response which was
able to control the parasite burden during the acute and the
chronic phase of the infection. Significantly reduced parasitemia
and cardiac pathology with increased levels of splenic IFN-γ-
producing cells were also observed by Barroso el al. during
the acute phase of AhR KO mice infected with Y strain of
T. cruzi, although they not observed significant differences in
Treg cells compared with WT mice (61). Surprisingly, in our
experimental model AhRd mice were protected from the Th1-
dependent liver pathology. Here we showed that these mice
developed a Treg-independent mechanism of Th1 constriction
between 10- and 17-days pi. After day 10 pi, serum levels of
IL-10 were increased and spleen CD4+ cells secreting IL-10
were significantly up-regulated in AhRd vs. WT mice. Increased
levels of CD4+ IL-10 producing T cells were also observed in
AhR KO mice during the acute phase of T. cruzi infection (61).
Likewise, IL-10 production by liver CD4+ T cells and increased
levels of serum IL-10 were also found after Plasmodium berghei
Anka infection in AhR KO mice (64). We speculate that the
population of CD4+ IL-10-secreting T cells that is increased
in T. cruzi-infected AhRd mice are different from Tr1 cells,
because the in vivo generation of Tr1 cells is strongly dependent
on AhR signals and these signals are very weak in AhRd mice
(65). Moreover, in our model we have observed that Lag-3 [a
marker of Tr1 cells (60)] is not up-regulated in the IL-10-
producing CD4+ cells, and that many of these cells are also IFN-
γ producers (data not shown). IL-10 production from effector
T cells represents an essential negative feedback mechanism in
the self-limitation of excessive inflammatory responses in many
infections (66–69). Thus, the relative amounts of IL-10 and IFN-
γ produced by Th1 cells may influence the balance between
clearance, persistent chronic infection or immunopathology (70,
71). It has been demonstrated that IL-10 producing Th1 cells,
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FIGURE 6 | AhR activation restricts the differentiation of CD8+ EM cells. Splenocytes from infected AhRd and WT mice were isolated at day 17 and 170 pi to
evaluate total CD8 and TSKB20/Kb-specific memory subpopulations by flow cytometry. (A) Representative plots and bars showing the percentage of splenocytes
from WT and AhRd mice bearing EM and CM phenotype on CD8+ and CD8+ TSKB20/Kb+ T cell populations at day 17 pi. Bars represent the mean values ± SD
with WT, n = 3 and AhRd, n = 4. (B) Percentage and absolute number of splenocytes CD8+ and CD8+ TSKB20/Kb+ from WT and AhRd mice at day 170 pi. Bars
represent the mean values ± SD with WT, n = 4 and AhRd, n = 4. (C) Representative plots showing CD44 and CD127 expression on splenocytes from WT and AhRd
mice gated on CD8+ TSKB20/Kb+ cell populations at day 170 pi gated as indicated in Figure S3 of Supplementary Material. Percentage of splenocytes from WT
and AhRd mice showing CD127+ and CD127- expression within CD8+ TSKB20/Kb+ CD44+ cell populations. Bars represent the mean values ± SD with WT, n = 4
and AhRd, n = 4. One experiment representative of at least three independent experiments is shown. P-values were calculated with two-tailed Student’s t-test.
*p < 0.05, **p < 0.01, ***p < 0.001.
also called self-regulatory Th1 cells, are activated early in a strong
inflammatory environment by repeated TCR triggering (high
antigen dose) and continued IL-12 action (72). Because fully
differentiated Th1 cells fail to up-regulate AhR after activation
and, therefore, cannot be directly modulated by AhR ligation,
we hypothesize that weak/lack AhR activation in DCs induces
differentiation signals that promote IL-10 production by CD4+
T cells. It has been demonstrated that AhR activation induces
tolerogenic properties to DCs. In fact, Quintana and others
have reported that AhR DC activation reduces the expression of
the pro-inflammatory cytokines IL-1β, IL-6, and IL-12 (12, 13).
In agreement, we have observed a higher IL-12 production by
Frontiers in Immunology | www.frontiersin.org 13 March 2019 | Volume 10 | Article 631
Ambrosio et al. AhR Immunoregulation During T. cruzi Infection
splenocytes from T. cruzi-infected AhRd vs. WT mice (data not
shown), and this has also been reported in T. cruzi-infected and
OVA-immunized AhR KO mice (61, 73).
Few studies have examined whether AhR signaling affects
the acquisition of immunological memory, but several
epidemiological studies have revealed that exposure to dioxins
and PCBs conditions low response to routine childhood
vaccinations (74–76). In accordance with this, our results
demonstrated a negative effect of a strong AhR activation on
the development of memory subsets, since the administration
of single dose of TCDD before T. cruzi infection decreased the
specific cellular response and prevented the accumulation of
memory cells by a mechanism that involve the death of activated
cells. Diminished memory response was also observed by TCDD
administration before primary influenza virus infection, (47, 77).
Even so, when TCDD is administered after the immunological
memory is established, there are no detectable effects on the
magnitude of the recall CD8+ T cell responses, suggesting that
AhR activation modulates critical events for the activation of
naïve T cells (47, 77), and as far as we know there are no reports
about the effect of AhR activation with ligands other than TCDD
on memory subsets development. Because antigen-experienced
cells suffered the direct effect of TCDD toxicity, no conclusions
can be drawn regarding the effects of AhR ligation on the
development of memory subsets during the acute phase of
T. cruzi infection. Therefore, we considered that weak AhR
ligation with 3-HK plus ITE and AhRd mice are good models
to study the development of CD8+ T cell memory subsets in
this infection. Interestingly, 3HK plus ITE activation of AhR
decreased the percentage of total and specific CD8+ splenic T
cells that acquired EM and CM phenotype while the lack/very
weak activation of AhR in AhRd mice showed opposite results.
Certainly, at the chronic phase of the infection, AhRd mice
had significantly higher frequency of splenic cells expressing
IL-7 receptor (CD127), a marker for long-living memory T
cells that would allow their vigorous proliferation driven by
the homeostatic cytokine IL-7 (78). Together, these results
suggest that AhR ligation restricts the differentiation of CD8+
memory T cells. Like other persistent infections, during T.
cruzi infection the CD8+ T cells are maintained primary by
the presence of antigen, and thus have phenotype of EM over
CM as observed in transient infections (79). Interestingly, 3-HK
plus ITE treated mice showed diminished number of EM cells
compared with untreated mice, although the former have more
parasite load able to drive preferably EM phenotype in CD8+ T
cells, thus supporting the role of AhR activation on restricting
memory development.
Different studies suggest that, similar to its indirect role on
Th1 cells, AhR would likely regulate DCs rather than directly
CD8+ T cells (47, 80). The very low expression of AhR in
most CD8+ T cell populations might support the lack of direct
regulation of CD8+ T cells by the AhR signaling. Thus, DCs may
be the main cell population capable of sensing and secreting AhR
ligands during T. cruzi infection, and the lack, weak or strong
activation of DC AhR might modulate their activation status,
inducing either proinflammatory or tolerogenic net effects on
T cells and modulating memory subsets development (3, 4, 81,
82). Taken together, our results allow us to propose a model in
which a threshold of AhR activation exist. Thus, signals above
the threshold (corresponding to WT B6 mice) would induce
tolerogenic properties in DCs (12, 13), restrict the development
of memory CD8+ T cells and promote Treg cells (as observed
here by treatment of B6 mice with 3-HK plus ITE or TCDD)
able to prematurely control Th1-type response. On the contrary,
signals below threshold would promote an early inflammatory
Th1-type response able to restrict the parasite replication and
its timely contraction by non-Tr1 IL-10 producing cells. Thus,
AhR induce diverse regulatory pathways that finally impacts on
parasite replication and infection outcome.
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